Bradley W Blaser, MD, PhD

Bradley W Blaser, MD, PhD

Physician

Specialty:Hematology

Gender: Male

Academic Title: Assistant Professor in the College of Medicine

Research Program: Leukemia and Hematologic Malignancies

  • About Me

    I am a member of the Leukemia and Hematologic Malignancies Program at the OSUCCC – James, where I seek to identify factors in the hematopoietic niche that promote the development of myeloid neoplasia. My current research involves using samples from the OSUCCC Leukemia Tissue Bank to find candidate genes that will be screened for effects on blood stem cells in the zebrafish system using genetic gain- and loss-of-function approaches. Cell biological and molecular mechanisms are then studied down to the single cell level using time-lapse video microscopy, flow cytometry and next-generation sequencing techniques to identify factors that may be useful in improving hematopoietic reconstitution in patients undergoing hematopoietic stem cell transplantation. I have co-authored many articles in scientific journals such as Blood, Leukemia Research and Journal of Immunology, and have presented my findings to the American Society of Hematology and the International Congress of Immunology.

  • Clinical Expertise

    • Hematology
  • Education & Training

    Fellowship - Hematology & Oncology

    • Boston Children's Hospital
      300 Longwood Ave, Boston, MA

    Internship - Internal Medicine

    • Brigham & Women's Abdominal Imaging Fellowship
      75 Francis St, Boston, MA

    Residency - Internal Medicine

    • Brigham & Women's Abdominal Imaging Fellowship
      75 Francis St, Boston, MA

    Fellowship - Hematology & Oncology

    • Dana-Farber Cancer Institute
      44 Binney St, Boston, MA

    Medical School

    • Ohio State University College of Medicine
      370 W 9Th Ave, Columbus, OH
  • Academic Office & Contact Information

    Academic Office:

    Comprehensive Cancer Center 0424
    410 W 12th Ave
    Columbus, Ohio 43210-1214

  • Videos

  • Publications

    April 15, 2024

    CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival.

    Wedig J, Jasani S, Mukherjee D, Lathrop H, Matreja P, Pfau T, D'Alesio L, Guenther A, Fenn L, Kaiser M, Torok MA, McGue J, Sizemore GM, Noonan AM, Dillhoff ME, Blaser BW, Frankel TL, Culp S, Hart PA, Cruz-Monserrate Z, Mace TA

    Cancer Immunol Immunother

    January 9, 2024

    Resistance to PRMT5-targeted therapy in mantle cell lymphoma.

    Long ME, Koirala S, Sloan S, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason C, Alinari L, Blaser BW, Baiocchi R

    Blood Adv

    January 1, 2024

    In vivo monitoring of leukemia-niche interactions in a zebrafish xenograft model.

    Arner A, Ettinger A, Blaser BW, Schmid B, Jeremias I, Rostam N, Binder-Blaser V

    PLoS One

    November 28, 2023

    Single-Cell RNA-Seq Analysis of Patient Myeloid-Derived Suppressor Cells and the Response to Inhibition of Bruton's Tyrosine Kinase.

    Savardekar H, Allen C, Jeon H, Li J, Quiroga D, Schwarz E, Wu RC, Zelinskas S, Lapurga G, Abreo A, Stiff A, Shaffer J, Blaser BW, Old M, Wesolowski R, Xin G, Kendra KL, Chung D, Carson WE

    Mol Cancer Res

    October 2, 2023

    Resistance to PRMT5 Targeted Therapy in Mantle Cell Lymphoma.

    Long ME, Koirala S, Sloan SL, Brown-Burke F, Weigel C, Villagomez L, Corps K, Sharma A, Hout I, Harper M, Helmig-Mason J, Tallada S, Chen Z, Scherle P, Vaddi K, Chen-Kiang S, Di Liberto M, Meydan C, Foox J, Butler D, Mason CE, Alinari L, Blaser BW, Baiocchi RA

    Blood Adv

    May 18, 2023

    Microenvironmental control of hematopoietic stem cell fate via CXCL8 and protein kinase C.

    Binder V, Li W, Faisal M, Oyman K, Calkins DL, Shaffer J, Teets EM, Sher S, Magnotte A, Belardo A, Deruelle W, Gregory TC, Orwick S, Hagedorn EJ, Perlin JR, Avagyan S, Lichtig A, Barrett F, Ammerman M, Yang S, Zhou Y, Carson WE, Shive HR, Blachly JS, Lapalombella R, Zon LI, Blaser BW

    Cell Rep

    January 6, 2023

    Dysregulation of PRMT5 in chronic lymphocytic leukemia promotes progression with high risk of Richter's transformation.

    Hing ZA, Walker JS, Whipp EC, Brinton L, Cannon M, Zhang P, Sher S, Cempre CB, Brown F, Smith PL, Agostinelli C, Pileri SA, Skinner JN, Williams K, Phillips H, Shaffer J, Beaver LP, Pan A, Shin K, Gregory CT, Ozer GH, Yilmaz SA, Harrington BK, Lehman AM, Yu L, Coppola V, Yan P, Scherle P, Wang M, Pitis P, Xu C, Vaddi K, Chen-Kiang S, Woyach J, Blachly JS, Alinari L, Yang Y, Byrd JC, Baiocchi RA, Blaser BW, Lapalombella R

    Nat Commun

    July 13, 2022

    A sumoylation program is essential for maintaining the mitotic fidelity in proliferating mantle cell lymphoma cells.

    Hanel W, Lata P, Youssef Y, Tran H, Tsyba L, Sehgal L, Blaser BW, Huszar D, Helmig-Mason J, Zhang L, Schrock MS, Summers MK, Chan WK, Prouty A, Mundy-Bosse BL, Chen-Kiang S, Danilov AV, Maddocks K, Baiocchi RA, Alinari L

    Exp Hematol Oncol

    July 7, 2022

    BMX Kinase Mediates Gilteritinib Resistance in FLT3-mutated AML through Microenvironmental Factors.

    Buelow DR, Bhatnagar B, Orwick S, Jeon JY, Eisenmann ED, Stromatt JC, Pabla N, Blachly JS, Baker SD, Blaser BW

    Blood Adv

    September 1, 2021

    Inhibition of MET Signaling with Ficlatuzumab in Combination with Chemotherapy in Refractory AML: Clinical Outcomes and High-Dimensional Analysis.

    Wang VE, Blaser BW, Patel RK, Behbehani GK, Rao AA, Durbin-Johnson B, Jiang T, Logan AC, Settles M, Mannis GN, Olin R, Damon LE, Martin TG, Sayre PH, Gaensler KM, McMahon E, Flanders M, Weinberg V, Ye CJ, Carbone DP, Munster PN, Fragiadakis GK, McCormick F, Andreadis C

    Blood Cancer Discov

    September 4, 2020

    Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.

    Underwood B, Zhao Q, Walker AR, Mims AS, Vasu S, Long M, Z Haque T, Blaser BW, Grieselhuber NR, Wall SA, Behbehani GK, Blachly JS, Larkin K, Byrd JC, Garzon R, Wang TF, Bhatnagar B

    Int J Hematol Oncol

    June 1, 2020

    CD200 promotes immunosuppression in the pancreatic tumor microenvironment.

    Choueiry F, Torok M, Shakya R, Agrawal K, Deems A, Benner B, Hinton A, Shaffer J, Blaser BW, Noonan AM, Williams TM, Dillhoff M, Conwell DL, Hart PA, Cruz-Monserrate Z, Bai XF, Carson Iii WE, Mace TA

    J Immunother Cancer

  • Consulting and Related Relationships

    At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Blaser has reported no relationships with companies or entities.